Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 May;123(6):1475-1488.
doi: 10.1002/jso.26359.

Pancreas cancer: Therapeutic trials in metastatic disease

James W Smithy  1 , Eileen M O'Reilly  1
Affiliations
Review

Pancreas cancer: Therapeutic trials in metastatic disease

James W Smithy et al. J Surg Oncol. 2021 May.

Abstract

Metastatic pancreatic ductal adenocarcinoma (PDAC) is a major cause of cancer-related mortality in 2021. Cytotoxic therapies are the therapeutic mainstay for PDAC. The recent approval of olaparib as maintenance therapy for germline BRCA1/2-mutated PDAC and pembrolizumab for mismatch repair deficient PDAC represent molecularly targeted approaches for this disease. Investigational therapeutic strategies include targeting the stroma, metabolism, tumor microenvironment, and the immune system, and selected approaches are reviewed herein.

Keywords: KRAS; clinical trials; genetics; metastatic disease; pancreatic cancer.

PubMed Disclaimer

References

    1. Siegel RL, Miller KD, Jemal A: Cancer statistics, 2020. CA Cancer J Clin 2020;70:7–30. - PubMed
    1. Mizrahi JD, Surana R, Valle JW, Shroff RT: Pancreatic cancer. Lancet 2020;395:2008–2020. - PubMed
    1. Conroy T, Desseigne F, Ychou M, et al. : FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011;364:1817–1825. - PubMed
    1. Von Hoff DD, Ervin T, Arena FP, et al. : Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 2013;369:1691–1703. - PMC - PubMed
    1. Pusceddu S, Ghidini M, Torchio M, et al. : Comparative Effectiveness of Gemcitabine plus Nab-Paclitaxel and FOLFIRINOX in the First-Line Setting of Metastatic Pancreatic Cancer: A Systematic Review and Meta-Analysis. Cancers (Basel) 2019;11. - PMC - PubMed

MeSH terms